BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Foreign Institutional Investors (FIIs) extended their selling on December 30 as they sold equities worth Rs 3844 crore, while Domestic Institutional Investors (DIIs) bought equities of Rs 6159 crore, ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Cue Biopharma Inc. (NASDAQ: CUE) witnessed a dramatic sell-off in its stock price after the clinical-stage biotechnology firm disclosed the terms of a substantial public equity offering. The ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...

Cue Biopharma Inc. Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include ...

Oil and gas exploration, development and production.